Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
June 12, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
June 10, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
June 04, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 09, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
Surrozen Provides First Quarter 2024 Financial Results and Business Update
May 08, 2024 16:05 ET
|
Surrozen, Inc.
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
April 03, 2024 08:40 ET
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
April 01, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
April 01, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Announces up to $192.5 Million Private Placement of Securities
Priced At-the-Market Under Nasdaq Rules
Surrozen Provides Corporate Update on Clinical Programs
January 18, 2024 08:30 ET
|
Surrozen, Inc.
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...
Surrozen Provides Third Quarter 2023 Financial Results
November 08, 2023 16:05 ET
|
Surrozen, Inc.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...